Search

Displaying results 1911 - 1920 of 7535 in total
  1. Drug

    Dichloroacetic acid

    go.drugbank.com/drugs/DB08809
    ApprovedInvestigationalWithdrawn

    A phase 1 study in 5 patients concluded that DCA was safe, but wasn't designed to establish effectiveness. … Early reports of its activity against brain cancer cells led patients to treat themselves with DCA, which is commercially available in non-pharmaceutical grade.

  2. Drug

    Sibutramine

    go.drugbank.com/drugs/DB01105
    ApprovedIllicitWithdrawn

    It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the United States. … In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug increases the risk of heart attack and stroke in patients with a history of heart disease.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  3. Drug

    Iloperidone

    go.drugbank.com/drugs/DB04946
    ApprovedInvestigational

    Iloperidone is a benzisoxazole [A263557] and an atypical antipsychotic agent that was first approved by the FDA on May 6, 2009. … [A263547] Iloperidone is currently used to treat schizophrenia and manic or mixed episodes associated with bipolar disorder.[L50527]

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  4. Drug

    Cerivastatin

    go.drugbank.com/drugs/DB00439
    ApprovedWithdrawn

    On August 8, 2001 the U.S. … Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from

  5. Drug

    Alvimopan

    go.drugbank.com/drugs/DB06274
    ApprovedInvestigational

    It is used to avoid postoperative ileus following small or large bowel resection and accelerates the gastrointestinal recovery period.

  6. Drug

    Homatropine

    go.drugbank.com/drugs/DB11181
    Approved

    use has not been approved by the FDA to be safe and effective. … Homatropine hydrobromide has been administered as ophthalmic solutions as a cycloplegic to temporarily paralyze accomodation, and to induce mydriasis (the dilation of the pupil); however such therapeutic

  7. Drug

    Voclosporin

    go.drugbank.com/drugs/DB11693
    ApprovedInvestigational

    [L31218] This [cyclosporine] A analog was approved by the FDA on January 22, 2021 following promising results in clinical trials. … Early intervention with voclosporin coupled with a kidney response is believed to prevent irreversible damage to the kidney and lead to better long-term clinical outcomes for patients with LN.

  8. Drug

    Gadobutrol

    go.drugbank.com/drugs/DB06703
    ApprovedInvestigational

    Due to its physicochemical properties, gadobutrol is formulated at twice the gadolinium ion concentration compared to other GBCA and thus requires a lesser injection volume. … of NSF thanks to the macrocyclic structures that limit dechelation of gadolinium.

  9. Drug

    Tisagenlecleucel

    go.drugbank.com/drugs/DB13881
    ApprovedInvestigational

    It was granted approval by FDA in August 2017 under the market name Kymriah. … These CD19-directed chimeric antigen receptors (CD19 CAR-T cells) direct the T cells to target and kill leukemia cells that express CD19 on the cell surface.

  10. Drug

    Acipimox

    go.drugbank.com/drugs/DB09055
    ApprovedInvestigational

    Acipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL. … Long-term administration is associated with reduced mortality, but unwanted effects limit its clinical use.